{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=35", "query": { "condition": "Genetic Change", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 1795, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T05:33:09.538Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01915498", "title": "Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematologic Neoplasms" ], "interventions": [ { "name": "Enasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2013-08-27", "completion_date": "2023-10-31", "has_results": true, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 19, "location_summary": "Duarte, California • Stanford, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01915498" }, { "nct_id": "NCT06123338", "title": "A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Adenocarcinoma", "HER2 Gene Mutation" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nutrition questionnaires (optional)", "type": "OTHER" }, { "name": "stool and saliva samples (optional)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2024-02-01", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 10, "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06123338" }, { "nct_id": "NCT04913285", "title": "A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Non-small Cell Lung Cancer", "Melanoma" ], "interventions": [ { "name": "KIN-2787", "type": "DRUG" }, { "name": "KIN-2787 and binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pierre Fabre Medicament", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2021-08-04", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 15, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04913285" }, { "nct_id": "NCT04598321", "title": "BrUOG 390: Neoadjuvant Treatment With Talazoparib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRCA1 Mutation", "BRCA2 Mutation", "Ovarian Cancer", "Fallopian Tube Cancer", "High Grade Serous Carcinoma" ], "interventions": [ { "name": "Talazoparib Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2021-03-29", "completion_date": "2022-12-06", "has_results": true, "last_update_posted_date": "2023-10-12", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 2, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04598321" }, { "nct_id": "NCT04955938", "title": "A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "IDH Mutation", "IDH1 Mutation", "IDH2 Gene Mutation", "Blood Cancer", "Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Fedratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-29", "completion_date": "2023-06-07", "has_results": false, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04955938" }, { "nct_id": "NCT02729298", "title": "First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "EGFR Positive Non-small Cell Lung Cancer", "Colorectal Carcinoma", "Recurrent Ovarian Carcinoma", "BRAF-Mutated Melanoma" ], "interventions": [ { "name": "TP-0903", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2016-12-14", "completion_date": "2022-06-29", "has_results": false, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 16, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02729298" }, { "nct_id": "NCT04673448", "title": "Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "BRCA-Associated Malignant Neoplasm", "BRCA Hereditary Ovarian Carcinoma", "Metastatic BRCA Hereditary Breast Carcinoma", "Metastatic Breast Carcinoma", "Metastatic Fallopian Tube Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Ovarian Carcinoma", "Metastatic Pancreatic Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Unresectable Breast Carcinoma", "Unresectable Fallopian Tube Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Ovarian Carcinoma", "Unresectable Pancreatic Carcinoma", "Unresectable Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" }, { "name": "Niraparib", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-10-18", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04673448" }, { "nct_id": "NCT02194387", "title": "Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Body Mass Index 25 or Greater", "BRCA1 Gene Mutation", "BRCA2 Gene Mutation", "Breast Carcinoma", "Cancer Survivor", "Chronic Lymphocytic Leukemia", "Fatigue", "Health Status Unknown", "Lynch Syndrome", "Ovarian Carcinoma", "Overweight" ], "interventions": [ { "name": "Dietary Intervention", "type": "DIETARY_SUPPLEMENT" }, { "name": "Internet-Based Intervention", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Telephone-Based Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 337, "start_date": "2014-09-17", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194387" }, { "nct_id": "NCT03043508", "title": "Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Genetic Mutation", "MEN1" ], "interventions": [ { "name": "Chart Review", "type": "OTHER" }, { "name": "Questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2015-04-10", "completion_date": "2026-04-01", "has_results": false, "last_update_posted_date": "2019-05-23", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03043508" }, { "nct_id": "NCT00003863", "title": "Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "comparative genomic hybridization", "type": "GENETIC" }, { "name": "cytogenetic analysis", "type": "GENETIC" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "gene rearrangement analysis", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 391, "start_date": "1999-06", "completion_date": "2005-05", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-11-15T05:33:09.538Z", "location_count": 69, "location_summary": "Anniston, Alabama • La Jolla, California • San Diego, California + 52 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003863" } ] }